Summary : This Venn diagram compares the overlapping and distinct symptoms of three major psychiatric disorders—recurrent major depression, schizophrenia and psychotic disorders, and bipolar disorders—highlighting their shared impact on decreased level of functioning. venn diagram: # Disorders Compared : • Recurrent major depression • Schizophrenia and psychotic disorders • Bipolar disorders # Symptom Lists : ## Recurrent major depression : • Depressive mood • Cognitive symptoms, attention and memory deficits • Delusions, hallucinations • Psychomotor restlessness or impairment • Suicidality ## Schizophrenia and psychotic disorders : • Depressive mood, loss of pleasure • Cognitive symptoms from multiple domains • Delusions, hallucinations • Psychomotor restlessness • Negative symptoms • Suicidality ## Bipolar disorders : • Elevated or depressive mood • Cognitive symptoms, attention and memory deficits • Delusions, hallucinations • Psychomotor restlessness or impairment • Suicidality # Central Overlap (Shared Features) : • Decreased level of functioning (illustrated by a person sitting with head down) • Delusions, hallucinations • Psychomotor restlessness or impairment • Suicidality • Cognitive symptoms # Design Encodings : • Three overlapping circles, each shaded differently and labeled with the disorder name. • Central overlap contains an illustration of a person and the phrase “Decreased level of functioning.” • Each disorder’s symptoms are listed in bullet points within its respective circle. • ESC logo in the bottom right corner. # Analysis : • All three disorders share several core symptoms: cognitive impairment, delusions/hallucinations, psychomotor changes, and suicidality, which collectively contribute to decreased functioning. • Schizophrenia and psychotic disorders uniquely list “negative symptoms” and “loss of pleasure.” • Bipolar disorder uniquely includes “elevated mood.” • The diagram visually emphasizes the substantial overlap in symptoms and functional impairment among these psychiatric conditions.

This pathophysiology diagram illustrates the potential mechanisms of action for Acetylsalicylic Acid (ASA) in the treatment and prevention of mood disorders. The central element is the chemical structure of ASA, which branches out to four key neurological and immunological domains. 1) Neuroinflammation: ASA is associated with decreased levels of prostaglandin E2, proinflammatory cytokines, and oxidative stress biomarkers (COX-1/COX-2), while potentially influencing microglial activation and oligodendroglial differentiation. 2) COX System: The diagram depicts the direct inhibition of cyclooxygenase enzymes, leading to a downstream reduction in inflammatory mediators. 3) Neurotransmission: The visual indicates a role in rebalancing neurotransmitters via the arachidonic acid pathway (COX-2), interacting with mood stabilizers. 4) PPARα Pathways: ASA is shown to enhance neuroplasticity, brain-derived neurotrophic factor (BDNF) levels, and plaque clearance. Directional arrows signify the increase or decrease of specific biological processes and molecular markers, summarizing how ASA acts as a multi-target modulator within the central nervous system to alleviate symptoms of depression and bipolar disorder.

This composite educational graphic presents a neuroimaging correlation analysis in the context of Pediatric Bipolar Disorder (PBD) with depression. The top row features two sagittal MRI brain scans with blue highlighted regions of interest (ROIs) representing areas of significantly decreased Regional Homogeneity (ReHo). The scan at x = 0 (midline) highlights the medial frontal gyrus, while the scan at x = 42 identifies the right middle frontal gyrus. The bottom row displays corresponding scatter plots showing the relationship between Mood and Feelings Questionnaire (MFQ) scores on the x-axis and mean ReHo values on the y-axis. Both plots demonstrate a statistically significant negative correlation: the left plot (medial frontal gyrus) shows r = -0.519, p = 0.033, and the right plot (right middle frontal gyrus) shows r = -0.627, p = 0.007. This visualization illustrates the pathophysiology of depression in PBD patients, linking clinical symptom severity (MFQ scores) with specific functional neuroimaging biomarkers in the prefrontal cortex.

This anatomical diagram provides a sagittal and three-quarter view of the human brain, specifically illustrating the functional neuroanatomy involved in bipolar disorder and emotional regulation. Key regions are color-coded to distinguish between cognitive control networks and limbic/para-limbic systems. The cognitive control regions, typically exhibiting reduced responsiveness in euthymic bipolar patients, include the Dorsolateral Prefrontal Cortex (DLPFC) in green, the Dorsomedial Prefrontal Cortex (DMPFC) in yellow, and the Dorsal Anterior Cingulate Cortex (ACC) in orange. In contrast, limbic and para-limbic areas associated with emotional regulation and increased responsiveness are highlighted, including the Ventral ACC in purple, the Ventrolateral Prefrontal Cortex (VLPFC) in light blue, and the amygdala, located deep within the temporal lobe, in red/pink. The diagram emphasizes the spatial relationships between the cortical prefrontal areas and subcortical structures like the amygdala and brainstem. This visual resource is designed for medical education regarding the pathophysiology of mood disorders, illustrating the imbalance between top-down volitional control and bottom-up emotional reactivity.

A pathophysiology diagram illustrating the 'Monoamine Deficiency Hypothesis' of depression. On the left, the chemical structures of three key monoamine neurotransmitters are shown: Serotonin (5-HT), Norepinephrine (NE), and Dopamine (DA). Each neurotransmitter is accompanied by a downward-pointing red arrow, indicating quantitative deficiency or reduced levels in the synaptic cleft or extracellular fluid. Red directional arrows point from these molecules toward a central clinical outcome box labeled 'Depressive Symptoms.' To the right, an illustration of a human face with a somber expression is paired with a bulleted list of common clinical manifestations, including consistently low mood, hopelessness, increased irritability, changed eating patterns, and trouble with concentration. The diagram effectively maps the biochemical theory of monoamine dysregulation to the neuropsychiatric presentation of Major Depressive Disorder (MDD), serving as an educational summary of the biological basis for antidepressant pharmacotherapy targeting monoamine reuptake or degradation.

The image displays three representative high-performance liquid chromatography (HPLC) chromatograms (labeled A, B, and C) used to measure monoamine neurotransmitters and their metabolites. Panel A shows a standard solution with clearly resolved and labeled peaks for MHPG, Norepinephrine (NE), Epinephrine (EPI), DOPAC, Normetanephrine (NM), Dopamine (DA), 5-HIAA, Isoprenaline (ISO), HVA, 3-MT, and Serotonin (5-HT). Panels B and C illustrate microdialysis samples obtained from a biological model. Panel B represents the baseline (pre-treatment) sample, showing significantly lower peak amplitudes for most monoamines compared to the standard. Panel C demonstrates the neurochemical profile after the infusion of 1 mM imipramine, a tricyclic antidepressant. Visually, Panel C shows a marked increase in the peak height and area for Serotonin (5-HT) and Norepinephrine (NE) relative to Panel B, reflecting the drug's mechanism as a reuptake inhibitor. This comparison serves as an educational tool for analytical chemistry and pharmacology, demonstrating how microdialysis and HPLC are used to monitor real-time changes in interstitial neurotransmitter concentrations following pharmacological intervention.

This medical illustration comprises two panels detailing the role of Vesicular Monoamine Transporter 2 (VMAT2) in neurotransmitter synthesis, storage, and release within the central nervous system. The left panel is a biochemical flowchart illustrating the metabolic pathways for three major monoamines: Dopamine (synthesized from Tyrosine via L-DOPA by Tyrosine Hydroxylase and AAAC), Histamine (from Histidine via Decarboxylase), and Serotonin/5-HT (from Tryptophan via Tryptophan Hydroxylase and AAAC). It shows VMAT2 facilitating the uptake of these neurotransmitters into storage vesicles. The right panel depicts a presynaptic terminal showing the active transport mechanism where VMAT2 utilizes an H+ gradient, generated by a vesicular ATP-synthase (V-ATPase), to sequester monoamines. The diagram illustrates neurotransmitter exocytosis into the synaptic cleft towards postsynaptic receptors and includes pharmacological modulation, showing Tetrabenazine (TBZ) as a VMAT2 inhibitor that blocks vesicular sequestration. Visual legends identify Dopamine (DA), Norepinephrine (NE), Histamine (His), and Serotonin (5-HT). This educational material focuses on neuropharmacology and synaptic physiology, suitable for medical students and neuroscience researchers.